CSIMarket Company Name, Ticker, Suppliers, else..


Roivant Sciences Ltd   (NASDAQ: ROIV)
Other Ticker:  
 

Roivant Sciences Ltd

ROIV's Fundamental analysis



Looking into Roivant Sciences Ltd growth rates, revenue grew by 154.96 % in I. Quarter 2024 from the same quarter a year ago. Ranking at No. 81

Major Pharmaceutical Preparations industry recorded growth of revenues by 5.18 %

Roivant Sciences Ltd realized net income compared to net loss a year ago in I. Quarter 2024

• More on ROIV's Growth


Roivant Sciences Ltd
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Roivant Sciences Ltd PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 1.98 in trailing twelve-month period.
Company
1.91
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 53.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.19.


• More on ROIV's Valuation
 
 Total Debt (Millions $) 324
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Revenue/Employee (TTM) $ 158,303
 Net Income/Employee (TTM) $ 4,616,541
 Receivable Turnover (TTM) -
 Tangible Book Value (Per Share $) 7.37

Roivant Sciences Ltd
current PE on trailing twelve month basis is above Major Pharmaceutical Preparations industry average.

Roivant Sciences Ltd PEG ratio is at -0 Company is currently trading with Price to Cash flow multiple of 1.98 in trailing twelve-month period.
Company
1.91
PE TTM   
Industry
-
PE TTM    
Company's Price to Sales ratio is at 53.03.
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.19.

Roivant Sciences Ltd Price to Book Ratio is at 1.42 lower than Industry Avg. of 78.62. and higher than S&P 500 Avg. of 0.01

• More on ROIV's Valuation

•  Market Capitalization (Millions $) 8,395
•  Shares Outstanding (Millions) 782
•  Employees 1,000
•  Revenues (TTM) (Millions $) 158
•  Net Income (TTM) (Millions $) 4,617
•  Cash Flow (TTM) (Millions $) 4,244
•  Capital Exp. (TTM) (Millions $) -2
•  Total Debt (Millions $) 324
•  Dividend TTM ($) 0 $
•  Dividend Yield TTM (%) -
•  Revenue/Employee (TTM) $ 158,303
•  Net Income/Employee(TTM) $ 4,616,541
•  Receivable Turnover Ratio (TTM) -
•  Tangible Book Value (Per Share $) 7.37

•  Market Capitalization (Millions $) 8,395
•  Shares Outstanding (Millions) 782
•  Employees 1,000
•  Revenues (TTM) (Millions $) 158
•  Net Income (TTM) (Millions $) 4,617
•  Cash Flow (TTM) (Millions $) 4,244
•  Capital Exp. (TTM) (Millions $) -2





  Ratio
•   Capital Ratio (MRQ) 27.91
•  Total Debt to Equity (MRQ) 0.05
•  Tangible Leverage Ratio (MRQ) 0.18
•  Asset Turnover Ratio (TTM) 0.03
•  Inventory Turnover Ratio (TTM) -





Roivant Sciences Ltd net profit margin of 104.28 % is currently ranking no. 12 in Major Pharmaceutical Preparations industry, ranking no. 17 in Healthcare sector and number 63 in S&P 500.

• More on ROIV's Key Ratios





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com